TRVI Earnings Prediction
The chart below shows how TRVI performed 10 days before and after its earnings report, based on data from the past quarters. Typically, TRVI sees a +7.93% change in stock price 10 days leading up to the earnings, and a -6.29% change 10 days following the report. On the earnings day itself, the stock moves by +1.41%. This data can give you a slight idea of what to expect for the next quarter's release.
TRVI Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
-0.13
-62.50%
8.33%
No Data Available
TRVI Earnings Analysis
Trevi Therapeutics, Inc. Common Stock Corporation (TRVI.O) Earnings Conference Call
Positive
Cash Reserves Stability: 1. Strong Cash Position: As of September 30, 2024, Trevi Therapeutics reported cash, cash equivalents, and marketable securities totaling $65.5 million, providing a cash runway into the second half of 2026.
Phase 2a Trial Enrollment: 2. Clinical Development Progress: The company has fully enrolled its Phase 2a RIVER trial in refractory chronic cough (RCC) with approximately 60 patients, and expects to report data in Q1 2025.
Key Data Readouts Ahead: 3. Upcoming Data Readouts: Trevi anticipates key data readouts, including the Human Abuse Potential (HAP) study results in December 2024 and the sample size re-estimation for the CORAL trial by year-end 2024, which are critical for future development.
Market Opportunity in RCC: 4. Significant Market Opportunity: The RCC condition affects approximately 2 to 3 million U.S. adults, highlighting a substantial unmet need for effective therapies, which Trevi aims to address with its unique treatment approach.
Leadership Team Enhancement: 5. Experienced Leadership Team: The appointment of Jim Cassella as Chief Development Officer brings over 35 years of experience in CNS therapies, enhancing Trevi's capabilities in advancing its clinical programs.
Negative
Rising Net Loss: 1. Increased Net Loss: Trevi Therapeutics reported a net loss of $13.2 million for Q3 2024, a significant increase from the $7.7 million loss in the same quarter of 2023.
R&D Expense Increase: 2. R&D Expense Surge: Research and development expenses rose to $11.2 million in Q3 2024, up from $6.3 million in Q3 2023, reflecting heightened clinical development activities.
Cash Reserves Decline: 3. Declining Cash Reserves: As of September 30, 2024, Trevi's cash, cash equivalents, and marketable securities decreased to $65.5 million, down from $83 million at the end of 2023.
Projected Cash Burn Analysis: 4. Projected Cash Burn: The company anticipates a cash burn of $41 million to $43 million for 2024, indicating ongoing financial strain as they continue to fund clinical trials.
Trial Enrollment Concerns: 5. Uncertain Trial Outcomes: The upcoming sample size re-estimation in the IPF cough trial could lead to a potential increase in patient enrollment from 160 to as high as 400, raising concerns about the trial's efficacy and future direction.
TRVI FAQs
How does TRVI typically perform around its earnings report dates?
Is Trevi Therapeutics, Inc. (TRVI) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
TRVI Earning Call Sentiment
Trevi Therapeutics, Inc. (TRVI) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
TRVI.O
4.87%Positive
Trevi's financial performance shows a widening net loss and increasing R&D expenses, raising financial concerns. Despite having a cash runway into 2026, the cash burn is high, and any trial delays could jeopardize this. The Q&A reveals unclear management responses, especially on drug liking evidence and DEA timelines, which might worry investors. Competitive pressures and potential trial halts further exacerbate risks. Although there is no market cap data, the negative financial and strategic outlook suggests a potential stock decline in the range of -2% to -8%.
